keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin lymphoma

keyword
https://www.readbyqxmd.com/read/28874597/risk-of-febrile-neutropenia-associated-with-select-myelosuppressive-chemotherapy-regimens-in-a-large-community-based-oncology-practice
#1
Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H Page, Chun Chao
Background: NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based primarily on clinical trial evidence. Many chemotherapy regimens, however, remain unclassified by NCCN or lack FN incidence data in real-world clinical practice. Patients and Methods: We evaluated incidence proportions of FN and grade 4 and 3/4 neutropenia during the first chemotherapy course among patients from Kaiser Permanente Southern California who received selected chemotherapy regimens without well-established FN risk...
September 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28614905/long-term-follow-up-of-chemoimmunotherapy-with-rituximab-oxaliplatin-cytosine-arabinoside-dexamethasone-road-in-patients-with-relapsed-cd20-b-cell-non-hodgkin-lymphoma-results-of-a-study-of-the-mayo-clinic-cancer-center-research-consortium-mccrc-mc0485-now
#2
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, Paul J Kurtin, Levi D Pederson, Dennis F Moore, Nassim H Nabbout, Daniel A Nikcevich, Kendrith M Rowland, Axel Grothey
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m(2) IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 - 5; oxaliplatin 130 mg/m(2) IV day 2; cytarabine 2000 mg/m(2) IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4...
October 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28454330/high-bim-mrna-levels-are-associated-with-longer-survival-in-advanced-gastric-cancer
#3
Nandie Wu, Ying Huang, Zhengyun Zou, Ana Gimenez-Capitan, Lixia Yu, Wenjing Hu, Lijing Zhu, Xia Sun, Jose Javier Sanchez, Wenxian Guan, Baorui Liu, Rafael Rosell, Jia Wei
Chemotherapy drugs, including 5-fluorouracil (5-FU), oxaliplatin and docetaxel, are commonly used in the treatment of gastric cancer (GC). Apoptosis-relevant genes may be associated with drug resistance. In the present study, the messenger RNA (mRNA) expression levels of B-cell lymphoma 2 interacting mediator of cell death (BIM), astrocyte elevated gene-1 (AEG-1) and AXL receptor tyrosine kinase (AXL) were investigated in 131 advanced GC samples, and the expression levels of these genes were correlated with patients' overall survival (OS)...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28381416/a-phase-2-3-multicenter-randomized-open-label-study-to-compare-the-efficacy-and-safety-of-lenalidomide-versus-investigator-s-choice-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
#4
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, Nina Wagner-Johnston, Randy D Gascoyne, Graham W Slack, Pierre Brousset, David A Eberhard, Francisco J Hernandez-Ilizaliturri, Gilles Salles, Thomas E Witzig, Pier Luigi Zinzani, George W Wright, Louis M Staudt, Yandan Yang, P Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D Lewis
Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Experimental Design: Patients with DLBCL who received ≥2 prior therapies were stratified by DLBCL subtype [germinal center B-cell (GCB) vs. non-GCB; determined by immunohistochemistry (IHC)] and then randomized 1:1 to lenalidomide (25 mg/day, 21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide, or oxaliplatin)...
April 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28215935/comparative-study-of-l-asparaginase-based-lop-regimen-over-chop-regimen-before-radiotherapy-for-stage-iie-extranodal-nasal-type-nk-t-cell-lymphoma-a-study-of-2-centers
#5
Limin Huang, Bin Yuan, Haixia Wu, Hongliang Chu, Yayun Liu, Shuang Wu, Hong Li, He Lu, Hui Chen
BACKGROUND: In this study we evaluated the efficacy of an L-asparaginase-based LOP (L-asparaginase, vincristine, and dexamethasone) regimen in extranodal Natural Killer (NK)/T-cell lymphoma (ENKTL) patients in the Guizhou province of China. PATIENTS AND METHODS: Forty-eight patients were treated with the LOP (L-asparaginase, vincristine and dexamethasone) regimen chemotherapy (CT) and 32 patients with the CHOP (cyclophosphamide, tetrahydropyanyl adriamycin, vincristine, and prednisone) regimen...
March 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28194060/retrospective-study-of-pegaspargase-gemicitabine-oxaliplatin-and-dexamethasone-peg-gemod-as-a-first-line-therapy-for-advanced-stage-extranodal-nk-t-cell-lymphoma
#6
Yi-Yun Yao, Yong Tang, Yan Zhuang, Li-Fang Zou, Hong-Ju Dou, Lei Wang, Qi Zhu
This study was conducted to retrospectively investigate the efficacy and safety of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) combination chemotherapy as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma (ENKTL). Eighteen patients with newly diagnosed stage III/IV ENKTL were subjected to 3-6 cycles of Peg-GemOD chemotherapy. After 3 cycles of therapy, the overall response rate was 67 % (12/18) with a complete response rate of 28 % (5/18) and a partial response rate of 39 % (7/18)...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28093003/outcome-for-patients-with-relapsed-refractory-aggressive-lymphoma-treated-with-gemcitabine-and-oxaliplatin-with-or-without-rituximab-a-retrospective-multicentre-study
#7
Vijay Dhanapal, Menaka Gunasekara, Chia Lianwea, Robert Marcus, Corinne De Lord, Stella Bowcock, Stephen Devereux, Piers Patten, Deborah Yallop, David Wrench, Paul Fields, Shireen Kassam
The treatment of relapsed aggressive lymphoma remains a challenge. Platinum-containing chemotherapy is standard of care. Gemcitabine/oxaliplatin (Gem-Ox) with or without rituximab (R) is an outpatient regimen with a favorable toxicity profile. This retrospective 'real world' study reports outcomes for 44 unselected patients with relapsed/refractory aggressive lymphoma treated with Gem-Ox ± R. 41% had primary refractory disease. The overall response rate (ORR) was 43% with a complete response (CR) of 30%...
September 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27917702/effectiveness-of-pegaspargase-gemcitabine-and-oxaliplatin-p-gemox-chemotherapy-combined-with-radiotherapy-in-newly-diagnosed-stage-ie-to-iie-nasal-type-extranodal-natural-killer-t-cell-lymphoma
#8
Wen Wei, Ping Wu, Li Li, Zhi-Hui Zhang
PURPOSE: Extranodal natural killer/T-cell lymphoma (ENKTL), nasal-type, is a distinct subtype of non-Hodgkin lymphoma. ENKTL is sensitive to radiotherapy, but the prognosis is poorer than those of other types of early stage lymphoma. To date, optimal treatment strategies for patients with early stage ENKTL have not been fully defined. METHODS: We retrospectively investigated the efficacy and safety of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) combined with different dose radiotherapy (RT) in the treatment of 35 newly diagnosed, stage IE to IIE ENKTL patients at our institution from October 2011 to September 2015...
July 2017: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/27757832/pixantrone-a-review-in-relapsed-or-refractory-aggressive-non-hodgkin-s-lymphoma
#9
REVIEW
Gillian M Keating
Pixantrone (Pixuvri(®)) is an aza-anthracenedione with a novel mode of action that is conditionally approved in the EU for use as monotherapy in adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL). In the randomized, open-label, multinational, phase 3 PIX301 trial in patients with multiply relapsed or refractory aggressive NHL, the complete response (CR) plus unconfirmed CR (uCR) rate at the end of treatment (primary endpoint) was significantly higher with intravenous pixantrone monotherapy than with a single-agent comparator (vinorelbine, oxaliplatin, ifosfamide, etoposide, mitoxantrone or gemcitabine)...
October 2016: Drugs
https://www.readbyqxmd.com/read/27377614/comparative-toxicities-of-3-platinum-containing-chemotherapy-regimens-in-relapsed-refractory-lymphoma-patients
#10
F Tixier, F Ranchon, A Iltis, N Vantard, V Schwiertz, E Bachy, F Bouafia-Sauvy, C Sarkozy, J F Tournamille, E Gyan, G Salles, C Rioufol
Optimal salvage chemotherapy regimen for patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma remains unclear but often based on platinum regimens. This retrospective study assesses in real life the toxicities profiles of patients with relapsed or refractory lymphoma treated with DHA (dexamethasone, high dose aracytine cytarabine) plus platinum salt (dexamethasone-High dose aracytine (cis)platin (DHAP), dexamethasone-High dose aracytine carboplatin (DHAC), or dexamethasone-High dose aracytine Oxaliplatin (DHAOX)), from February 2007 to May 2013 in 2 French hospitals...
July 5, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27354597/enhanced-tlr4-expression-on-colon-cancer-cells-after-chemotherapy-promotes-cell-survival-and-epithelial-mesenchymal-transition-through-phosphorylation-of-gsk3%C3%AE
#11
Yoon Hee Chung, Daejin Kim
BACKGROUND: Phosphorylation of glycogen synthase kinase 3β (GSK3β) by phosphatidyl-inositide 3-kinase (PI3K)/protein kinase B (AKT) or inhibition of GSK3β with small-molecule inhibitor attenuates cell survival and proliferation and increases apoptosis in most cancer cell lines. In this study, we investigated the role of phosphorylated GSK3β activated by enhanced toll-like receptor 4 (TLR4) expression in drug-treated colon cancer cells as a model of post-chemotherapy cancer cells. MATERIALS AND METHODS: The effect of TLR4 stimulation on metastasis and apoptosis in drug-exposed colon cancer cells was determined by real-time polymerase chain reaction (PCR) and immunoblotting...
July 2016: Anticancer Research
https://www.readbyqxmd.com/read/27239738/efficacy-and-tolerance-of-pegaspargase-gemcitabine-and-oxaliplatin-with-sandwiched-radiotherapy-in-the-treatment-of-newly-diagnosed-extranodal-nature-killer-nk-t-cell-lymphoma
#12
Xiao-Mei Jing, Zhi-Hui Zhang, Ping Wu, Shi-Chuan Zhang, Yuan-Rong Ren, Zhu-Juan Xiong, Wen Wei, Lei Luo, Li Li
Extranodal nature killer (NK)/T cell lymphoma (ENKL), nasal type, is a highly aggressive and heterogeneous disease. Here we report a retrospective study of 38 newly-diagnosed ENKL patients treated with pegaspargase, gemcitabine, oxaliplatin (P-Gemox) and sandwiched radiotherapy in our department during 2012-2016. A median of 4 (range, 2-6) (total=141) cycles of P-Gemox were administered. Interim restaging after at least 2 cycles showed complete remission (CR) rate of 23.68%, partial remission (PR) rate of 63...
August 2016: Leukemia Research
https://www.readbyqxmd.com/read/27220900/efficacy-of-the-gemox-r-regimen-leads-to-the-identification-of-oxaliplatin-as-a-highly-effective-drug-against-mantle-cell-lymphoma
#13
Antònia Obrador-Hevia, Margalida Serra-Sitjar, José Rodríguez, Lamiae Belayachi, Leyre Bento, Marta García-Recio, Jose María Sánchez, Priam Villalonga, Antonio Gutiérrez, Silvia Fernández de Mattos
Mantle Cell Lymphoma (MCL) is an aggressive lymphoma subtype that accounts for 6-8% of non-Hodgkin lymphomas. The disease is mostly incurable and characterized by a continuous pattern of relapse. Major changes have recently been implemented in the management of MCL, but continuous relapses still mark this disease as a challenge for clinicians. We previously reported the efficacy of GemOx-R (Gemcitabine, Oxaliplatin and Rituximab) in patients with refractory and relapsing MCL. We present results for a larger series with longer follow-up and including high-risk frontline patients, showing an overall response rate of 83%...
September 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27149123/flavopiridol-induces-apoptosis-via-mitochondrial-pathway-in-b16f10-murine-melanoma-cells-and-a-subcutaneous-melanoma-tumor-model
#14
Ozlem Gokce, Irem Dogan Turacli, Hacer Ilke Onen, Ozlem Erdem, Elif Erguven Kayaa, Abdullah Ekmekci
Flavopiridol is a cyclin-dependent kinase (CDK) inhibitor that promotes cell cycle arrest. We aimed to examine the anti-proliferative effects of the flavopiridol and oxaliplatin combination on p16INK4A deficient melanoma cells B16F10 and also its apoptotic effects on a subcutaneously injected B16F10 allograft melanoma tumor model. Flavopiridol and oxaliplatin treated B16F10 cell viability was determined by MTT assay. C57BL6 mice were injected with B16F10 cells and treated with flavopiridol after tumor implantation...
April 2016: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/27093153/efficacy-of-combined-gemcitabine-oxaliplatin-and-pegaspargase-p-gemox-regimen-in-patients-with-newly-diagnosed-advanced-stage-or-relapsed-refractory-extranodal-nk-t-cell-lymphoma
#15
Jing-Hua Wang, Liang Wang, Cheng-Cheng Liu, Zhong-Jun Xia, Hui-Qiang Huang, Tong-Yu Lin, Wen-Qi Jiang, Yue Lu
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Asparaginase-based regimens are recommended for patients with advanced-stage or relapsed/refractory ENKTL. We retrospectively investigated the efficacy and toxicity of combined gemcitabine, oxaliplatin, and pegaspargase (P-gemox) in these patients. A total of 35 patients with newly diagnosed stage III-IV, relapsed or refractory ENKTL were treated with 2 to 8 cycles of P-gemox: gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) injected intravenously and pegaspargase (2500 IU/m2) injected intramuscularly on day 1 and repeated every 2 weeks...
May 17, 2016: Oncotarget
https://www.readbyqxmd.com/read/27072578/analysis-of-the-efficacy-and-safety-of-a-combined-gemcitabine-oxaliplatin-and-pegaspargase-regimen-for-nk-t-cell-lymphoma
#16
Jing-Hua Wang, Hua Wang, Yan-Jun Wang, Zhong-Jun Xia, Hui-Qiang Huang, Wen-Qi Jiang, Yue Lu
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Novel L-asparaginase-based treatment regimens, such as GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown promising results against stage IE/IIE ENKTL. To define the general applicability of P-gemox, in a retrospective analysis we examined the efficacy and safety of P-gemox in a cohort of 117 patients with newly diagnosed or relapsed/refractory ENKTL...
June 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/26966416/synchronous-rectal-adenocarcinoma-and-splenic-marginal-zone-lymphoma
#17
T Srikumar, M Markow, B Centeno, S Hoffe, J Tao, H Fernandez, J Strosberg, D Shibata
Synchronous cancers of different primary origin are rare. Here, we describe the case of a patient with concomitant diagnoses of rectal adenocarcinoma and splenic marginal zone lymphoma (smzl). A 57-year-old woman initially presented with abdominal pain. Physical examination and computed tomography demonstrated massive splenomegaly, and a complete blood count revealed microcytic anemia and lymphopenia. During the subsequent evaluation, she presented with hematochezia, melena, and constipation, which prompted gastroenterology referral...
February 2016: Current Oncology
https://www.readbyqxmd.com/read/26956432/biweekly-dose-dense-gemcitabine-oxaliplatin-and-dexamethasone-for-relapsed-refractory-aggressive-non-hodgkin-lymphoma-a-multicenter-single-arm-phase-ii-trial
#18
MULTICENTER STUDY
Jae-Cheol Jo, Jin Ho Baek, Je-Hwan Lee, Young-Don Joo, Sung-Hwa Bae, Jung-Lim Lee, Jung-Hee Lee, Dae-Young Kim, Won-Sik Lee, Hun Mo Ryoo, Yunsuk Choi, Hawk Kim, Kyoo-Hyung Lee
AIM: We performed a phase II study to evaluate the efficacy of combination chemotherapy consisting of gemcitabine, dexamethasone and oxaliplatin (GemDOx) as a biweekly regimen and salvage therapy in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). METHODS: Gemcitabine (1000 mg/m(2) ) and oxaliplatin (85 mg/m(2) ) were administered intravenously on days 1 and 15, and dexamethasone (40 mg) was administered orally on days 1-4. RESULTS: Twenty-nine patients were enrolled, and most patients had diffuse large B-cell lymphoma (n = 18)...
June 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26848703/thymoquinone-from-nigella-sativa-seeds-promotes-the-antitumor-activity-of-noncytotoxic-doses-of-topotecan-in-human-colorectal-cancer-cells-in-vitro
#19
Rana Khalife, Mohammad Hassan Hodroj, Rajaa Fakhoury, Sandra Rizk
Topotecan, a topoisomerase I inhibitor, is an anticancer drug widely used in the therapy of lung, ovarian, colorectal, and breast adenocarcinoma. Due to the primary dose-limiting toxicity of topotecan, which is myelosuppressive, it is necessary to identify other chemotherapeutic agents that can work synergistically with topotecan to increase its efficacy and limit its toxicity. Many studies have shown synergism upon the combination of topotecan with other chemotherapeutic agents such as gemcitabine. Other studies have demonstrated that pre-exposing cells to naturally occurring compounds such as thymoquinone, followed by gemcitabine or oxaliplatin, resulted in higher growth inhibition compared to treatment with gemcitabine or oxaliplatin alone...
March 2016: Planta Medica
https://www.readbyqxmd.com/read/26846320/oxaliplatin-pharmacokinetics-on-hemodialysis-in-a-patient-with-diffuse-large-b-cell-lymphoma
#20
LETTER
Michael S Balzer, Hendrik Eggers, Michael Heuser, Ansgar Reising, Anna Bertram
No abstract text is available yet for this article.
March 2016: Annals of Hematology
keyword
keyword
9105
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"